Your browser doesn't support javascript.
loading
Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation.
Wagenaar, Timothy R; Zabludoff, Sonya; Ahn, Sung-Min; Allerson, Charles; Arlt, Heike; Baffa, Raffaele; Cao, Hui; Davis, Scott; Garcia-Echeverria, Carlos; Gaur, Rajula; Huang, Shih-Min A; Jiang, Lan; Kim, Deokhoon; Metz-Weidmann, Christiane; Pavlicek, Adam; Pollard, Jack; Reeves, Jason; Rocnik, Jennifer L; Scheidler, Sabine; Shi, Chaomei; Sun, Fangxian; Tolstykh, Tatiana; Weber, William; Winter, Christopher; Yu, Eunsil; Yu, Qunyan; Zheng, Gang; Wiederschain, Dmitri.
Afiliación
  • Wagenaar TR; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Zabludoff S; Regulus Therapeutics, San Diego, California.
  • Ahn SM; Asan Medical Center, Seoul, Republic of Korea.
  • Allerson C; Regulus Therapeutics, San Diego, California.
  • Arlt H; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Baffa R; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Cao H; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Davis S; Regulus Therapeutics, San Diego, California.
  • Garcia-Echeverria C; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Gaur R; Genzyme R&D Center, Framingham, Massachusetts.
  • Huang SM; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Jiang L; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Kim D; Asan Medical Center, Seoul, Republic of Korea.
  • Metz-Weidmann C; Sanofi BioInnovation, Nucleic Acid Therapeutics Platform, Frankfurt, Germany.
  • Pavlicek A; Regulus Therapeutics, San Diego, California.
  • Pollard J; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Reeves J; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Rocnik JL; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Scheidler S; Sanofi BioInnovation, Nucleic Acid Therapeutics Platform, Frankfurt, Germany.
  • Shi C; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Sun F; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Tolstykh T; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Weber W; Genzyme R&D Center, Framingham, Massachusetts.
  • Winter C; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Yu E; Asan Medical Center, Seoul, Republic of Korea.
  • Yu Q; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Zheng G; Sanofi Oncology, Cambridge, MA Massachusetts.
  • Wiederschain D; Sanofi Oncology, Cambridge, MA Massachusetts. Dmitri.Wiederschain@sanofi.com.
Mol Cancer Res ; 13(6): 1009-21, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25758165
ABSTRACT
UNLABELLED Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options available to cancer patients. MicroRNA 21-5p (miR-21) has been shown to be upregulated in HCC, but the contribution of this oncomiR to the maintenance of tumorigenic phenotype in liver cancer remains poorly understood. We have developed potent and specific single-stranded oligonucleotide inhibitors of miR-21 (anti-miRNAs) and used them to interrogate dependency on miR-21 in a panel of liver cancer cell lines. Treatment with anti-miR-21, but not with a mismatch control anti-miRNA, resulted in significant derepression of direct targets of miR-21 and led to loss of viability in the majority of HCC cell lines tested. Robust induction of caspase activity, apoptosis, and necrosis was noted in anti-miR-21-treated HCC cells. Furthermore, ablation of miR-21 activity resulted in inhibition of HCC cell migration and suppression of clonogenic growth. To better understand the consequences of miR-21 suppression, global gene expression profiling was performed on anti-miR-21-treated liver cancer cells, which revealed striking enrichment in miR-21 target genes and deregulation of multiple growth-promoting pathways. Finally, in vivo dependency on miR-21 was observed in two separate HCC tumor xenograft models. In summary, these data establish a clear role for miR-21 in the maintenance of tumorigenic phenotype in HCC in vitro and in vivo. IMPLICATIONS miR-21 is important for the maintenance of the tumorigenic phenotype of HCC and represents a target for pharmacologic intervention.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Oligorribonucleótidos Antisentido / MicroARNs / Proliferación Celular / Redes Reguladoras de Genes / Neoplasias Hepáticas Límite: Animals Idioma: En Revista: Mol Cancer Res Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Oligorribonucleótidos Antisentido / MicroARNs / Proliferación Celular / Redes Reguladoras de Genes / Neoplasias Hepáticas Límite: Animals Idioma: En Revista: Mol Cancer Res Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2015 Tipo del documento: Article